A narrative review, where the authors discuss in-depth the evolution and practical usage of immunotherapeutics using hybridoma technology.

The paper is seen in the American Journal of Biopharmacy and Pharmatceutical Sciences published by Scientific Scholar

A focused and extremely specific treatment for a wide range of ailments, including cancer, autoimmune disorders, and infectious diseases, immunotherapeutics based on antibody and hybridoma technologies

have completely changed the practice of medicine.

By harnessing the immune system’s strength and fusing it with cutting-edge biotechnology, this method creates monoclonal antibodies (mAbs), which are therapeutic agents that mAbs are molecules created

in a laboratory that resembles the immune system’s naturally occurring antibodies.

This research offers a thorough analysis of immunotherapeutics with a focus on hybridomas. It describes how focused and precise treatments for a variety of illnesses, such as cancer, autoimmune disorders,

and infectious diseases, have been made possible by immunotherapeutics, which are based on antibody and hybridoma technology.

The hybridoma technology process, is a heterogeneous population of cells that produce unique mAbs are created by combining immortalized myeloma cells with B lymphocytes. To isolate and create drug

formulations, the hybridoma cells that produce the desired antibodies are chosen and grown in large numbers.

Hybridoma technology is used in the treatment of autoimmune conditions, viral infections and cancer. The importance of immunotherapeutics based on antibody and hybridoma technologies is revolutionizing the treatment environment and creating new opportunities for customized and targeted therapies.

This news is covered by Medical Dialogues